SynthesisFrontiers in endocrinology2026
The crosstalk between polycystic ovary syndrome and Hashimoto thyroiditis: a systematic review and meta-analysis.
Synthesis in Frontiers in endocrinology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Polycystic ovary syndrome (PCOS) and Hashimoto thyroiditis (HT) are endocrine disorders; when they co-exist, they exacerbate each other's serious consequences. Literature is scarce on these important diseases. This meta-analysis aimed to assess the prevalence of HT in both patients with PCOS and control subjects, as well as insulin resistance (IR) and lipid profile in patients with PCOS with and without HT. Methods: We systematically searched PubMed, Embase, Web of Science, and Google Scholar from inception to February 2026 using combinations of keywords and MeSH terms related to polycystic ovary syndrome, Hashimoto thyroiditis, autoimmune thyroid disease, insulin resistance, and metabolic outcomes. We retrieved 209 articles, of which 38 full texts were screened, and 22 studies were included in the meta-analysis. Results: HT was higher in patients with PCOS compared to control subjects (OR = 2.69, 95% CI: 1.63 to 4.42), and women with PCOS and HT exhibited higher HOMA-IR than women with PCOS alone (MD = -0.92, 95% CI: -1.50 to -0.35). However, the TC, LDL, HDL, and TG were similar in patients with PCOS with and without HT (MD = -0.61, 95% CI: -1.40 to 0.18; MD = -0.49, 95% CI: -1.69 to 0.72; MD = 0.01, 95% CI: -0.09 to 0.07; and MD = -0.06, 95% CI: -0.35 to 0.23, respectively). Conclusion: HT was more prevalent among women with PCOS than in controls. Women with PCOS and concomitant HT had higher IR than women with PCOS alone. However, the TC, LDL, HDL, and TG were similar in patients with PCOS with and without HT. Prospective studies with long follow-up are needed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.